Beginning Cash: The amount of cash reported by the company on its previous statement.
Viridian Therapeutics, Inc. (VRDN) had Beginning Cash of $99.59M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$0.07M |
|
$-100.73M |
|
-- |
|
$0.07M |
|
$106.84M |
|
$-106.77M |
|
$6.03M |
|
$-100.73M |
|
$-100.73M |
|
$-100.73M |
|
$-100.73M |
|
$-100.73M |
|
$-100.73M |
|
$-106.77M |
|
$-108.31M |
|
81.59M |
|
81.59M |
|
$-1.00 |
|
$-1.00 |
|
| Balance Sheet Financials | |
$578.75M |
|
$1.09M |
|
$3.57M |
|
$582.32M |
|
$52.59M |
|
$12.35M |
|
$14.57M |
|
$67.16M |
|
$326.28M |
|
$515.17M |
|
$515.17M |
|
81.65M |
|
| Cash Flow Statement Financials | |
$-168.03M |
|
$175.78M |
|
$9.98M |
|
|
Beginning Cash |
$99.59M |
$117.32M |
|
$17.73M |
|
$21.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.01 |
|
-- |
|
-- |
|
0.02 |
|
0.04 |
|
100.00% |
|
-142356.00% |
|
-142356.00% |
|
-- |
|
-134313.30% |
|
-134313.30% |
|
$-168.15M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-30.87% |
|
-19.55% |
|
-17.30% |
|
-19.10% |
|
$6.31 |
|
$-2.06 |
|
$-2.06 |
|